Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration ...

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...

CLL incidence and prevalence have decreased globally, but regional disparities exist, with high-SDI regions seeing declines and low-SDI regions experiencing stable or increasing rates. Mortality ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...